Research Information Only — TB-500 is an investigational compound. Not approved by the FDA for human use. Content is for educational purposes only. Consult a qualified physician before use.
⚠ WADA NOTICE: Thymosin β4 (TB-500) is prohibited in-competition and out-of-competition under WADA Prohibited List S2.2 (Peptide Hormones & Related Substances). Competitive athletes: review the Prohibited List before use.
A synthetic analog of the endogenous thymic peptide Thymosin β4, TB-500 promotes tissue repair through actin sequestration, VEGF-driven angiogenesis, and progenitor cell activation — with the most advanced pharmaceutical development program in the research peptide space.
No FDA-approved formulation exists. RegeneRx Biopharmaceuticals holds an active IND for multiple Thymosin β4 programs. Compounded versions circulate in research markets without pharmaceutical oversight.
RegeneRx Clinical Program
Phase II Completed
Multiple Phase II Trials
RGN-259 (ophthalmic): Phase II positive signals in dry eye and neurotrophic keratitis. RGN-352 (systemic): Phase II cardiac post-STEMI — underpowered but mechanistic signal. RGN-137 (topical): chronic wound healing.
WADA Prohibited List
Prohibited S2.2
BANNED — In & Out of Competition
Thymosin β4 appears explicitly on the WADA Prohibited List under S2.2 (Peptide Hormones, Growth Factors, Related Substances). Prohibition applies year-round to all competitive athletes subject to WADA compliance.
Molecular Profile
Structure & Physical Properties
Active Domain
LKKTETQ
Residues 17–23 · Actin-binding heptapeptide
Sequence Length
43 Amino Acids
Full-length Thymosin β4 sequence
Molecular Weight
~4,965 Da
~5 kDa; peptide (not protein)
Origin
Endogenous
Naturally produced in platelets, macrophages, thymic epithelial cells; highest concentration in blood platelets (~0.5 mg/mL)
Source (Research)
Synthetic cGMP
Solid-phase peptide synthesis; lyophilized powder for reconstitution
Administration
SC / IM / Ocular
Subcutaneous or intramuscular injection; ophthalmic drops (RGN-259 formulation)
TB-500 ≠ Tuberculosis: The "TB" designation stands for "Thymosin Beta" — it has no connection to tuberculosis or any mycobacterial pathogen. TB-500 is a synthetic version of the naturally occurring human protein Thymosin β4, which is present throughout the body at its highest concentration in blood platelets.
Mechanism of Action
Four Pathways of Tissue Repair
TB-500 operates through distinct, complementary mechanisms that together address the cellular requirements for tissue healing: cell mobilization, vascular supply, inflammation control, and progenitor activation.
01
Actin Sequestration & Cell Migration
The LKKTETQ domain binds G-actin (monomeric actin), preventing polymerization into F-actin. This shifts the intracellular actin equilibrium, promoting lamellipodia formation and directed cell migration — the foundational requirement for tissue repair.
TB-500 upregulates Vascular Endothelial Growth Factor (VEGF) and its receptor VEGFR2, stimulating new blood vessel formation (angiogenesis). Enhanced vascular supply delivers oxygen and nutrients to healing tissue — critical for tendon, muscle, and cardiac repair.
Tβ4 downregulates NF-κB (the master inflammatory transcription factor), reducing TNF-α, IL-1β, and IL-6 production. This resolves excessive inflammation that would otherwise impair healing, while preserving the initial inflammatory phase necessary for tissue repair initiation.
In cardiac tissue, Tβ4 activates epicardial progenitor cells via the Wnt signaling pathway, driving their migration into damaged myocardium. In neural tissue, Tβ4 promotes oligodendrocyte progenitor differentiation. These effects represent the most novel therapeutic opportunities.
Understanding TB-500's pharmacokinetic profile is essential for interpreting its dosing requirements. The gap between its short plasma half-life and prolonged biological effects reflects downstream signaling persistence — a characteristic of receptor-mediated peptide action.
Plasma Half-Life (IV)
~2 Hours
Rapid clearance with IV administration; shorter than biological effect duration
Molecular Stability
Moderate
α-helical structure confers proteolytic resistance vs. linear peptides; degraded by serum proteases over hours
Primary Clearance
Renal / Hepatic
Small peptide fragments cleared renally; partial hepatic metabolism; impaired renal function extends exposure
Distribution
Systemic
Found in virtually all tissues post-administration; concentrates at sites of injury via actin-binding upregulation and platelet accumulation
Oral Bioavailability
Negligible
Destroyed by GI proteases; not orally bioavailable unlike BPC-157. Injectable or topical routes required.
The Signaling Persistence Effect: TB-500's plasma half-life of ~2 hours (IV) does not represent its biological window of action. VEGF gene expression upregulation, angiogenic sprouting cascades, and progenitor cell migration programs activated by Tβ4 binding persist for days to weeks after peptide clearance. This is why relatively infrequent dosing intervals in research protocols can still be associated with sustained signaling effects despite rapid plasma clearance — the mechanism, not any specific schedule, is what matters here.
Deep Dive
Angiogenesis: TB-500's Vascular Mechanism
The Biology
What Is Angiogenesis?
Angiogenesis is the formation of new blood vessels from pre-existing vasculature. It is required for tissue repair — without adequate blood supply, healing tissue cannot receive the oxygen and growth factors it needs. Wound healing, tendon repair, and cardiac recovery all depend critically on angiogenic signaling. VEGF is the primary molecular driver, acting on endothelial cells to trigger sprouting, migration, and tube formation.
The Mechanism
How TB-500 Drives It
Tβ4 upregulates both VEGF production and its receptor VEGFR2 on endothelial cells, amplifying the angiogenic signal. Simultaneously, the actin sequestration mechanism promotes endothelial cell migration — necessary for new vessel sprouting. Tβ4 also upregulates laminin-5 and metalloproteinases (MMP-2, MMP-9), which remodel extracellular matrix to permit vessel invasion. This dual action on both signal strength and cellular capacity for migration makes Tβ4's angiogenic effect particularly potent relative to single-pathway agents.
Clinical Relevance
Why This Matters
Poor vascularity is the central obstacle to tendon healing — tendons are among the most hypovascular tissues in the body. In cardiac post-MI repair, restoring blood supply to the border zone determines whether salvageable myocardium survives. For chronic wounds (diabetic ulcers, pressure injuries), failed angiogenesis is the primary barrier to closure. TB-500's VEGF-amplifying mechanism addresses all three contexts, which is why RegeneRx's clinical programs span ocular, cardiac, and wound-healing indications.
Stem Cell Biology
Hair Follicle Stem Cell Activation
Among TB-500's secondary mechanisms, its interaction with hair follicle stem cells is both the most widely discussed in research communities and among the least supported by clinical evidence — making accurate framing essential.
The Hair Cycle Connection
Anagen
Growth phase (2–6 years): Hair matrix cells proliferate rapidly; high actin dynamics. Tβ4 is expressed in anagen bulge cells and promotes their activation — the cell biology parallels Tβ4's core mechanism: actin remodeling drives cell migration from the follicle bulge.
Catagen
Regression phase (~2 weeks): Programmed apoptosis of follicle cells; Tβ4 expression decreases. Some researchers propose exogenous Tβ4 may delay catagen onset.
Telogen
Resting phase (~3 months): Follicle is quiescent. The proposed benefit of exogenous Tβ4 is reactivating stem cells in the bulge region to initiate early anagen entry — analogous to its progenitor-activation role in cardiac tissue.
1975 — Discovery
Thymosin β4 first isolated from thymus by Goldstein et al. Named for thymic origin; initial focus on immune modulation. No connection to hair biology noted.
2003 — Follicle Link
Cha et al. (J. Investigative Dermatology) identified Tβ4 expression in hair follicle bulge stem cells. Demonstrated that Tβ4 promotes hair follicle stem cell activation and anagen phase initiation in mouse models. Generated significant research community interest.
2010s — Wound Research Overlap
Sosne's ocular research and wound healing models incidentally noted hair regrowth adjacent to wound margins in animal models treated with Tβ4 — suggesting a systemic or paracrine effect on nearby follicles.
Present — Clinical Gap
No controlled human trials for hair restoration with systemic or topical TB-500. No RegeneRx indication in hair loss. Online anecdotal reports are numerous but uncontrolled. The mechanistic foundation is credible; clinical translation remains undemonstrated.
Mechanistic Plausibility vs. Clinical Reality: The biological rationale for TB-500 affecting hair follicle stem cells is credible — the same actin-remodeling and progenitor-activation mechanisms that drive cardiac and tendon healing logically apply to hair follicle stem cells, which are among the most extensively studied adult stem cell populations. However, a mechanistically plausible basis does not equate to demonstrated clinical efficacy. Individuals seeking evidence-based hair restoration should be directed toward FDA-approved treatments (minoxidil, finasteride, platelet-rich plasma in some guidelines) while acknowledging the ongoing investigational interest in Tβ4 for this indication.
Clinical Context
TB-500 vs. Biological Therapies: PRP & Beyond
The question practitioners and informed patients most often ask is not "does TB-500 work?" but "how does it compare to what I'd otherwise do?" For musculoskeletal injuries, that benchmark is platelet-rich plasma (PRP) — and the comparison reveals a biologically significant connection that is rarely acknowledged.
⚡ The PRP Connection: Blood platelets are the richest natural source of Thymosin β4 in the human body, containing approximately 0.5 mg/mL of endogenous Tβ4 — far higher than any other tissue. This means that PRP injections, by concentrating platelets 5–10× above baseline, inherently deliver a concentrated bolus of endogenous Tβ4 along with PDGF, TGF-β1, IGF-1, and other growth factors. The "biological plausibility" argument for PRP's clinical effects may in part reflect Tβ4 delivery — a connection almost entirely absent from the PRP clinical trial literature.
Autologous (no foreign substance); FDA-cleared device (preparation kit); covered in some protocols; Tβ4 delivered naturally; established physician procedure
Strong evidence for pain management; Level I across multiple conditions
Oral (no injection); well-understood; cost-effective; good for acute pain management
GI, cardiovascular, renal risks with chronic use; may impair tendon and bone healing with prolonged use by suppressing necessary inflammatory phase
Preclinical Evidence Summary
Healing Effect by Tissue Type
Approximate Healing Improvement vs. Control — Preclinical Models
Values represent approximate improvement in healing endpoints (closure rate, tensile strength, or functional recovery) versus vehicle control, aggregated from preclinical literature. Phase II clinical data (RGN-259) reflects improvement in corneal staining scores in neurotrophic keratitis. Values are approximate and may vary substantially across study designs, species, and endpoints. Not a direct head-to-head comparison across tissue types.
Evidence Summary
Key Studies & Trial Data
Study / Source
Design
Model / Population
Key Finding
Bock-Marquette et al., 2004 Nature
Animal
Mouse post-MI cardiac
Tβ4 activates epicardial progenitor cells post-infarction; improved cardiac function, reduced infarct size. First demonstration of cardiac regenerative mechanism in mammals.
RGN-259 Phase II (ARISE-2) RegeneRx, 2017
Phase II RCT
Neurotrophic keratitis (n=72)
Statistically significant improvement in corneal staining scores (NEI scale) and visual acuity vs. vehicle. Achieved primary endpoint. Most rigorous human data for Tβ4.
RGN-352 Phase II (STEMI) RegeneRx, 2013
Phase II RCT
Post-MI cardiac (n=107)
No significant difference in primary endpoint (LVEF at 90 days). Trial likely underpowered. Trend toward improved ejection fraction and lower biomarkers in Tβ4 arm; mechanistic data consistent with preclinical findings.
Xu et al., 2007 Journal of Immunology
Animal
Mouse inflammatory model
Tβ4 downregulates NF-κB activation, reducing TNF-α, IL-1β, and IL-6. Anti-inflammatory effect confirmed across multiple inflammatory challenge models.
Philp et al., 2004 Journal of Cell Science
In Vitro
Human fibroblasts / HUVECs
LKKTETQ domain alone recapitulates Tβ4's cell migration effect; binds G-actin with high affinity (Kd ~0.5 µM). Active domain definitively identified.
Malinda et al., 1999 FASEB Journal
Animal
Rat wound healing model
Tβ4 accelerated wound closure by ~42% vs. control. Increased neovascularization and collagen deposition at wound margins. First demonstration of in vivo wound healing effect.
Sosne et al., 2010 Investigative Ophthalmology
Animal
Alkali-injured rabbit cornea
Tβ4 eye drops accelerated corneal wound healing and reduced inflammation post-chemical injury. Directly supported the RGN-259 ophthalmic program development.
Gustavsson et al., 2013 PLOS ONE
Animal
Rat Achilles tendon model
Tβ4-treated tendons showed increased collagen type I expression and significantly greater tensile strength at 4 weeks vs. saline control. Supports use in tendon injury protocols.
Administration
Routes of Administration
💉
SC
Subcutaneous Injection
Most common research route
Slower absorption; sustained plasma levels
Suitable for maintenance and systemic protocols
🩹
IM
Intramuscular Injection
Higher peak plasma concentration
Faster onset vs. subcutaneous
More technique-dependent administration
👁️
Ophthalmic
Ocular Drops (RGN-259)
Site-specific — corneal and ocular surface
RGN-259: 0.1% Tβ4 ophthalmic solution
Dry eye / neurotrophic keratitis indication
Phase II demonstrated statistically significant benefit
Only route with positive RCT data in humans
Investigational Dosing
Human Dosing: Why None Is Published Here
No dose of TB-500 (Thymosin β4) has been established as safe or effective for self-directed use, and this page does not publish one. The only human dosing data with regulatory-grade rigor comes from RegeneRx's controlled clinical trials — a fixed, physician-administered protocol, not a template for individual use.
RGN-352 Phase II Trial Dose (IV)
1.5 mg
3 doses: within 24h of PCI, then day 3, day 7
The only dosing regimen for full-length Thymosin β4 studied under IRB oversight with a defined safety monitoring plan. Physician-administered IV in a post-MI hospital setting — not a subcutaneous self-administration protocol, and not transferable to any other use case.
RGN-259 Ophthalmic Trial Concentration
0.1%
Topical ocular solution, per trial protocol
Site-specific ocular formulation studied for dry eye and neurotrophic keratitis. The concentration and schedule are specific to that formulation and trial design — not applicable to systemic use.
On the ranges circulating online: Loading-phase, maintenance-phase, and "acute injury protocol" dose tables commonly seen in research-peptide forums and vendor materials are not derived from any published clinical trial. They reflect uncontrolled, self-reported use with unverified peptide purity and no safety monitoring. TB-500 has no FDA-approved dose for any indication, and this page will not publish self-administration amounts or frequencies. Anyone considering peptide use for any purpose should do so only under the supervision of a licensed physician.
Unique Mechanism
Cardiac Regenerative Properties
Epicardial Progenitor Cell Activation: TB-500's Most Novel Mechanism
The cardiac regenerative properties of Thymosin β4 represent one of the most scientifically compelling findings in the peptide research space — and also the most clinically challenging to translate. The 2004 Nature paper by Bock-Marquette et al. demonstrated that Tβ4 could activate dormant epicardial progenitor cells (EPCs) in the mammalian heart, causing them to migrate into damaged myocardium and differentiate into cardiomyocytes, smooth muscle cells, and endothelial cells.
The Wnt Signaling Pathway
Tβ4 promotes nuclear translocation of β-catenin via ILK (integrin-linked kinase) activation, engaging canonical Wnt signaling. In cardiac progenitor cells, Wnt pathway activation drives a cell fate program toward cardiomyogenic differentiation — a critical step normally suppressed in the adult mammalian heart.
Epicardial Progenitor Biology
The adult epicardium retains a quiescent population of cells expressing embryonic heart markers (Wt1, Tbx18). These "second heart field" progenitors can be reactivated by injury signals or exogenous stimuli including Tβ4. Once activated, they undergo epithelial-to-mesenchymal transition (EMT) and migrate into the myocardium.
The Translation Challenge
Despite compelling preclinical data, the Phase II RGN-352 trial in post-STEMI patients (n=107) did not meet its primary endpoint (change in LVEF at day 90). Likely reasons include: underpowered sample size, heterogeneous patient population, difficulty with systemic peptide delivery to cardiac tissue, and timing of treatment relative to injury.
Neural Progenitor Parallel
Tβ4 similarly activates oligodendrocyte progenitor cells in neural tissue, promoting myelination and axonal repair. Animal models of spinal cord injury and optic nerve crush show functional recovery with Tβ4 treatment. These findings make Tβ4 one of the few compounds with proposed mechanisms across both cardiac and neural regeneration.
RGN-352 Phase II Trial Summary (NCT01311518)
Randomized, double-blind, placebo-controlled trial in 107 patients with anterior STEMI. IV Thymosin β4 (1.5 g) within 24 hours of PCI, then 2 additional doses at days 3 and 7. Primary endpoint: change in LVEF from baseline to day 90 by MRI. Result: No statistically significant difference in LVEF (Tβ4: +2.8% vs. placebo: +2.1%, p=0.58). Trend toward reduced cardiac fibrosis in Tβ4 arm. Safety profile was favorable with no dose-limiting toxicities. Study widely considered underpowered; further development would require larger Phase III.
Safety Monitoring
Recommended Monitoring Framework
🩸
Hepatic Function
ALT / AST Panel
Baseline and at 8-week intervals. TB-500 undergoes partial hepatic metabolism; significant hepatic dysfunction could alter clearance. No hepatotoxic signal observed in clinical trials, but baseline important for risk assessment.
📊
Inflammatory Markers
CRP / IL-6 / ESR
Baseline inflammatory status helps distinguish treatment effect from underlying pathology. CRP normalization can serve as a functional response marker in musculoskeletal injury protocols. Useful in tracking the anti-inflammatory response over treatment course.
🫀
Cardiovascular
Blood Pressure / HR
+ VEGF Serum (optional)
VEGF upregulation theoretically affects vascular tone. Blood pressure monitoring is prudent, particularly at higher doses. Serum VEGF is an optional pharmacodynamic marker to confirm biological activity, though not part of standard safety monitoring.
🔬
Renal Function
BMP / Creatinine
Renal peptide clearance is significant for small peptides like Tβ4. Baseline renal function assessment is standard for any peptide protocol. Impaired renal function may extend half-life and increase systemic exposure above intended levels.
Patient Consideration
Candidate Profile
Potentially Appropriate Candidates
Adults with documented soft tissue injuries (tendon, ligament, muscle) under physician supervision
Individuals with chronic wound healing challenges unresponsive to standard care
Research participants in properly consented investigational studies
Post-surgical patients in supervised recovery programs where physician-directed peptide use is part of the protocol
Individuals with ocular surface conditions (under ophthalmologist supervision; RGN-259 pathway)
Strong Contraindications / Avoid
Competitive athletes subject to WADA-governed sport — use constitutes doping violation
Active malignancy — VEGF upregulation may theoretically promote tumor angiogenesis
Pregnancy or lactation — no safety data exists
Known hypersensitivity to peptide preparations
Uncontrolled cardiovascular disease without cardiologist oversight
Use of unverified non-pharmaceutical-grade sources — purity and dose accuracy cannot be confirmed
Stacking Considerations
TB-500 & BPC-157: Complementary Recovery Stack
🔗
Mechanistic Synergy in Tissue Repair
TB-500 and BPC-157 are the two most commonly co-administered research peptides in the recovery space — and the mechanistic rationale for combination use is robust. BPC-157 acts through the VEGFR2/Nitric Oxide pathway and enhances tendon-to-bone integration, while TB-500 acts through actin sequestration and VEGF upregulation, promoting cell migration and angiogenesis. BPC-157 has a stronger body of evidence for gastrointestinal protection and systemic anti-ulcer effects; TB-500 has more direct cellular migration data and the only human RCT (corneal). Together, they address complementary phases of the healing response: BPC-157's rapid anti-inflammatory and NO-mediated vasodilation, followed by TB-500's sustained angiogenic and cell migration support. No direct head-to-head or combination human trial exists; synergy data is extrapolated from complementary mechanisms and anecdotal research community reports.
What is TB-500 and how does it relate to Thymosin β4?
TB-500 is a research-market name for a synthetic version of Thymosin β4 (Tβ4), a naturally occurring 43-amino acid protein found throughout the human body — with the highest concentration in blood platelets (~0.5 mg/mL). The "TB" stands for Thymosin Beta, not tuberculosis. The key distinction is that Thymosin β4 is the endogenous human protein, while TB-500 refers to the commercial synthetic formulation used in research settings. Some researchers argue that TB-500 may primarily refer to the active fragment LKKTETQ (residues 17-23) rather than the full-length protein, though commercially available products are typically the complete 43-amino acid sequence. RegeneRx Biopharmaceuticals' pharmaceutical programs use the full-length Thymosin β4 under the trade names RGN-259, RGN-352, and RGN-137.
Is TB-500 legal for competitive athletes?
No. Thymosin β4 (including TB-500) is explicitly listed on the World Anti-Doping Agency (WADA) Prohibited List under Section S2.2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics. The prohibition applies both in-competition and out-of-competition. Any athlete competing in a sport governed by WADA (which includes virtually all Olympic sports and most major professional leagues globally) who uses TB-500 is subject to a doping violation, regardless of therapeutic intent. The existence of legitimate pharmaceutical research (RegeneRx) does not create a Therapeutic Use Exemption (TUE) for the compound at this time, as no approved clinical indication exists. Athletes: consult your national anti-doping organization before using any peptide preparation.
How does TB-500 compare to BPC-157 for tissue repair?
TB-500 and BPC-157 are mechanistically distinct and are often considered complementary rather than competing options. BPC-157 acts primarily through the VEGFR2/Nitric Oxide signaling pathway, is gastric-juice derived, has robust preclinical evidence across musculoskeletal, gastrointestinal, and CNS injury models, and appears to be orally bioavailable (which TB-500 is not). TB-500 acts through actin sequestration and direct VEGF upregulation, is the only peptide in this class with positive Phase II human RCT data (albeit for ocular use), and has better-characterized cardiac and neural progenitor mechanisms. BPC-157 has a broader evidence base across tissue types in animals; TB-500 has more advanced human pharmaceutical development. The research community commonly combines them in "recovery stacks," applying complementary mechanisms simultaneously.
Can TB-500 promote hair growth?
This is a frequently cited potential effect, but the evidence is limited. Thymosin β4 was identified in a 2003 paper in the Journal of Investigative Dermatology as being expressed in hair follicle stem cells and playing a role in activating these stem cells during the anagen (growth) phase of the hair cycle. This finding generated significant interest in Tβ4 as a potential hair-loss treatment. However, there are no controlled human trials demonstrating hair regrowth with systemic or topical TB-500. The mechanism is biologically plausible — Tβ4 activates quiescent stem cell populations, and hair follicle stem cells are a well-characterized stem cell niche — but translation from isolated cell findings to clinical hair restoration has not been demonstrated. RegeneRx has not pursued a hair-loss indication. Claims of dramatic hair regrowth from TB-500 in research communities are anecdotal.
What is the evidence for TB-500's cardiac regenerative effects?
The cardiac data for TB-500/Tβ4 has two distinct bodies of evidence: strong preclinical and a neutral Phase II clinical trial. The 2004 Nature study by Bock-Marquette et al. is landmark work, demonstrating for the first time that a peptide could activate mammalian cardiac progenitor cells and improve heart function post-infarction in mice. Subsequent preclinical studies confirmed VEGF-driven angiogenesis in cardiac tissue, anti-fibrotic effects, and progenitor cell mobilization via the Wnt/β-catenin and ILK pathways. However, the human Phase II trial (RGN-352, 107 post-STEMI patients) did not achieve its primary endpoint of improved ejection fraction at 90 days — though it showed a trend and a favorable safety profile. The disconnect between preclinical and clinical results is likely multifactorial: the trial was underpowered, systemic peptide delivery to ischemic cardiac tissue is challenging, and the patient population was heterogeneous. Further development would require a larger, better-powered Phase III trial with improved delivery strategy.
Is TB-500 the same compound as BPC-157?
No — they are entirely different peptides, although they are frequently confused or conflated in online discussions. BPC-157 is a pentadecapeptide (15 amino acids) derived from human gastric juice Body Protection Compound, with the sequence GEPPPGKPADDAGLV. TB-500 is a 43-amino acid synthetic Thymosin β4, an endogenous peptide produced in platelets and thymic tissue with the active domain LKKTETQ. They differ in origin, sequence, molecular weight (~1,419 Da vs. ~4,965 Da), mechanism of action, tissue selectivity, evidence base, and regulatory history. The only overlap is that both promote tissue healing and angiogenesis via different pathways — which is precisely why some researchers combine them.
Full Research Disclaimer
TB-500 (Thymosin β4) is not approved by the U.S. Food and Drug Administration or any major regulatory agency for use as a drug or dietary supplement in humans. All content on this page is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. The information presented reflects available preclinical and investigational research literature and should not be interpreted as endorsement of any particular use. Individual response to any compound varies considerably. Readers should consult with a qualified, licensed healthcare provider before considering any investigational compound. Regulatory status, legal classification, and WADA prohibited list status are subject to change; verify current status with relevant authorities before use. PeptideReport.ai does not manufacture, sell, or endorse any peptide preparations. Quality, purity, and dosing accuracy of commercially available "research peptides" are not independently verified and may vary substantially from stated specifications.
SD
Dr. Scott DelBoccio, DMD
Founding Author · PeptideReport.ai
Dr. Scott DelBoccio, DMD is a retired dentist with thirty years of clinical practice — including a hormone-therapy and regenerative wellness practice built around individual bloodwork, national lecturing on advanced dental and surgical techniques, mentoring new dentists on practice management, and innovating dental and laser procedures now used throughout North America — who is now heavily involved in peptide research and development, building beginner-to-advanced optimization frameworks calibrated to the individual, and holds workshops and lectures on peptide therapeutics for other clinicians and researchers. PeptideReport.ai was founded on the principle that E-E-A-T-compliant, physician-authored content is the appropriate standard for research-grade health information — particularly in the rapidly evolving peptide research space where accurate mechanistic understanding matters most. All compound profiles on this platform are research literature reviews, not clinical guidance.